Andrew A Lane
Overview
Explore the profile of Andrew A Lane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
5788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pemmaraju N, Konopleva M, Sweet K, Stein A, Rizzieri D, Wang E, et al.
Leuk Lymphoma
. 2025 Mar;
:1-4.
PMID: 40067964
No abstract available.
2.
Fay C, Hirner J, Shimony S, Bui A, Lane A, LeBoeuf N
J Am Acad Dermatol
. 2024 Nov;
92(3):628-630.
PMID: 39547322
No abstract available.
3.
Booth C, Bouyssou J, Togami K, Armand O, Rivas H, Yan K, et al.
JCI Insight
. 2024 Nov;
9(24).
PMID: 39499902
MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood...
4.
Kharfan-Dabaja M, Lane A, Pemmaraju N
Blood
. 2024 Oct;
145(6):567-576.
PMID: 39374520
Historically, treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN) were limited to conventional chemotherapy, adopted from regimens used to treat acute myeloid or acute lymphoblastic leukemias, or lymphomas. Nowadays,...
5.
Luo Q, Raulston E, Prado M, Wu X, Gritsman K, Whalen K, et al.
Nature
. 2024 May;
630(8015):198-205.
PMID: 38720074
Phosphoinositide-3-kinase-γ (PI3Kγ) is implicated as a target to repolarize tumour-associated macrophages and promote antitumour immune responses in solid cancers. However, cancer cell-intrinsic roles of PI3Kγ are unclear. Here, by integrating...
6.
Miller A, Rodriguez F, Langenbucher A, Lin L, Bray C, Duquette S, et al.
Commun Biol
. 2024 Apr;
7(1):483.
PMID: 38643279
Leukemias and their bone marrow microenvironments undergo dynamic changes over the course of disease. However, little is known about the circulation kinetics of leukemia cells, nor the impact of specific...
7.
Shimony S, Keating J, Fay C, Luskin M, Neuberg D, LeBoeuf N, et al.
Blood Adv
. 2024 Apr;
8(11):2803-2812.
PMID: 38603567
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) can involve skin, bone marrow (BM), central nervous system (CNS), and non-CNS extramedullary sites. Preclinical models demonstrated clonal advantage of TET2-mutated plasmacytoid dendritic cells...
8.
Daver N, Montesinos P, DeAngelo D, Wang E, Papadantonakis N, Todisco E, et al.
Lancet Oncol
. 2024 Feb;
25(3):388-399.
PMID: 38423051
Background: Pivekimab sunirine (IMGN632) is a first-in-class antibody-drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload. CD123 is overexpressed in several haematological malignancies, including acute...
9.
Pemmaraju N, Madanat Y, Rizzieri D, Fazal S, Rampal R, Mannis G, et al.
Leuk Lymphoma
. 2024 Feb;
65(5):548-559.
PMID: 38391126
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all...
10.
Luo Q, Raulston E, Prado M, Wu X, Gritsman K, Yan K, et al.
bioRxiv
. 2024 Feb;
PMID: 38328043
Phosphoinositide 3-kinase gamma (PI3Kγ) is implicated as a target to repolarize tumor-associated macrophages and promote anti-tumor immune responses in solid cancers. However, cancer cell-intrinsic roles of PI3Kγ are unclear. Here,...